Author: Igyártó, Botond Z; Jacobsen, Sonya; Ndeupen, Sonia
Title: Future considerations for the mRNA-lipid nanoparticle vaccine platform Cord-id: u7y2g1h1 Document date: 2021_4_24
ID: u7y2g1h1
Snippet: Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the ri
Document: Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.
Search related documents:
Co phrase search for related documents- adaptive immune response and adjuvant effect: 1, 2
- adaptive immune response and adjuvant property: 1
- adaptive immune response and adjuvant system: 1
- adaptive immune response and administration route: 1, 2
- adaptive immune response and lung inflammatory response: 1
- adaptive immune response and lung tissue: 1, 2, 3, 4, 5, 6, 7
- adaptive immune response and lymphoid organ: 1
Co phrase search for related documents, hyperlinks ordered by date